Inovio Pharmaceuticals (NASDAQ:INO) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• Inovio Pharmaceuticals' stock recently surpassed its 200-day moving average of $1.87, trading as high as $2.42, and currently sits at $2.28 with a trading volume of over 1.6 million shares.
• Analysts show mixed sentiments with Wall Street Zen downgrading the stock from "hold" to "sell," while Piper Sandler initiated coverage with an "overweight" rating and a price target of $5.00.
• Institutional investments are increasing, with significant increases in holdings by firms like Bank of America and Deutsche Bank, indicating potential long-term interest in Inovio Pharmaceuticals.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.87 and traded as high as $2.42. Inovio Pharmaceuticals shares last traded at $2.28, with a volume of 1,626,514 shares trading hands.

Analyst Ratings Changes

A number of analysts have recently commented on INO shares. Zacks Research cut Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, September 3rd. Piper Sandler started coverage on Inovio Pharmaceuticals in a research report on Wednesday, July 9th. They set an "overweight" rating and a $5.00 target price on the stock. Wall Street Zen cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Finally, HC Wainwright reiterated a "neutral" rating and set a $3.00 target price on shares of Inovio Pharmaceuticals in a research report on Thursday, August 14th. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $8.80.

Inovio Pharmaceuticals Trading Down 0.4%

The stock has a fifty day simple moving average of $1.91 and a two-hundred day simple moving average of $1.88. The company has a market cap of $122.22 million, a PE ratio of -0.88 and a beta of 1.62.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.02. As a group, equities research analysts anticipate that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 5,894 shares during the period. Bank of Montreal Can boosted its holdings in Inovio Pharmaceuticals by 23.7% during the second quarter. Bank of Montreal Can now owns 57,946 shares of the biopharmaceutical company's stock worth $118,000 after buying an additional 11,110 shares in the last quarter. Northern Trust Corp boosted its stake in Inovio Pharmaceuticals by 6.4% in the 4th quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company's stock worth $401,000 after purchasing an additional 13,269 shares during the period. Bank of New York Mellon Corp boosted its stake in Inovio Pharmaceuticals by 22.4% in the 1st quarter. Bank of New York Mellon Corp now owns 75,422 shares of the biopharmaceutical company's stock worth $123,000 after purchasing an additional 13,784 shares during the period. Finally, XTX Topco Ltd boosted its stake in Inovio Pharmaceuticals by 26.7% in the 1st quarter. XTX Topco Ltd now owns 66,169 shares of the biopharmaceutical company's stock worth $108,000 after purchasing an additional 13,939 shares during the period. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.